67 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug https://www.zacks.com/stock/news/2333625/travere-gains-11-on-securing-full-fda-nod-for-kidney-disease-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2333625 Sep 09, 2024 - The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
Relay Stock Soars on Upbeat Data From Breast Cancer Study https://www.zacks.com/stock/news/2334138/relay-stock-soars-on-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334138 Sep 10, 2024 - RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
What Makes Wolters Kluwer NV (WTKWY) a Good Fit for 'Trend Investing' https://www.zacks.com/stock/news/2194044/what-makes-wolters-kluwer-nv-wtkwy-a-good-fit-for-trend-investing?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2194044 Dec 06, 2023 - Wolters Kluwer NV (WTKWY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063 Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag https://www.zacks.com/stock/news/2200609/roche-s-rhhby-sbla-for-xolair-gets-fda-priority-review-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200609 Dec 20, 2023 - The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis https://www.zacks.com/stock/news/2205112/voyager-vygr-gains-on-gene-therapy-deal-with-novartis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205112 Jan 03, 2024 - Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More https://www.zacks.com/stock/news/2205605/biotech-stock-roundup-vygr-gains-from-nvs-deal-agio-up-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2205605 Jan 04, 2024 - Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
Top Analyst Reports for Merck, Salesforce & Philip Morris https://www.zacks.com/commentary/2206306/top-analyst-reports-for-merck-salesforce-philip-morris?cid=CS-ZC-FT-research_daily-2206306 Jan 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).
The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group https://www.zacks.com/stock/news/2206930/the-zacks-analyst-blog-highlights-merck-salesforce-philip-morris-international-novartis-and-cme-group?cid=CS-ZC-FT-press_releases-2206930 Jan 08, 2024 - Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.
Top Research Reports for Novartis, Amgen & Palo Alto Networks https://www.zacks.com/commentary/2214881/top-research-reports-for-novartis-amgen-palo-alto-networks?cid=CS-ZC-FT-research_daily-2214881 Jan 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW).

Pages: 1234567

<<<Page 5>